Schroder Adveq
Schroder Adveq is a leading asset manager investing in private equity globally.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Schroder Adveq Information
Geographic Data
Address: Affolternstrasse 56
City: Zurich
State: zurich
Zip: CH-8050
Country: CH
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Schroder Adveq was founded in 1997 and is a leading asset manager investing globally in private equity. Pension funds, insurance companies, endowments, family offices and other financial institutions located in Europe, North America and the Asia-Pacific region entrust us with their funds because of our solution-focused approach to private equity.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2020 | iOnctura | Series A | 16.6M |
| 6/2021 | Alentis Therapeutics | Series B | 66.8M |
| 7/2019 | Revolution Medicines | Series C | 100M |
| 7/2020 | MISSION Therapeutics | Venture Round | 15M |
| 7/2018 | Pliant Therapeutics | Series B | 0 |
| 11/2020 | Memo Therapeutics | Series B | 15.6M |
| 8/2019 | Araris Biotech | Seed Round | 2.6M |
| 12/2019 | ImmunOs Therapeutics | Series A | 0 |
| 9/2020 | Casma Therapeutics | Series B | 50M |
| 10/2020 | Araris Biotech | Seed Round | 0 |
| 7/2018 | Nohla Therapeutics | Series B | 11M |
| 7/2020 | iOnctura | Series A | 5.8M |
| 10/2018 | ImmunOs Therapeutics | Venture Round | - |
| 6/2022 | Lenskart | Series I | 0 |
| 11/2020 | Synendos Therapeutics | Series A | 0 |
| 5/2021 | Tessian | Series C | 65M |
| 6/2018 | Decibel Therapeutics | Series C | 55M |
| 5/2021 | HAYA Therapeutics SA | Seed Round | 18M |
| 6/2020 | Goldfinch Biopharma | Series B | 100M |
| 2/2022 | HAYA Therapeutics | Seed Round | 0 |
| 5/2021 | HAYA Therapeutics | Seed Round | 0 |
| 4/2019 | Alentis Therapeutics | Series A | 12.3M |
| 6/2022 | ImmunOs Therapeutics | Series B | 0 |
| 5/2018 | Memo Therapeutics | Series A | 5M |
| 3/2019 | IfChange | Series C | 80M |
| 10/2020 | Cedilla Therapeutics | Series B | 57.6M |
| 3/2020 | Pliant Therapeutics | Series C | 0 |
| 4/2018 | Revolution Medicines | Series B | 56M |
| 9/2017 | Amal Therapeutics | Series B | 9.5M |
| 11/2018 | Amal Therapeutics | Series B | 32.6M |
| 4/2021 | Bizongo | Series C | 0 |
| 1/2020 | Bizongo | Series C | 30M |
| 8/2021 | LEAP India | Secondary Market | 34M |
| 6/2022 | Lenskart | Series I | 0 |
| 6/2022 | ImmunOs Therapeutics | Series B | 0 |
| 2/2022 | HAYA Therapeutics | Seed Round | 0 |
| 8/2021 | LEAP India | Secondary Market | 0 |
| 6/2021 | Alentis Therapeutics | Series B | 0 |
| 5/2021 | Tessian | Series C | 0 |
| 5/2021 | HAYA Therapeutics | Seed Round | 0 |
| 4/2021 | Bizongo | Series C | 0 |
| 11/2020 | Synendos Therapeutics | Series A | 0 |
| 11/2020 | Memo Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
